Literature DB >> 24858722

Update on prognostic factors in acromegaly: Is a risk score possible?

E Fernandez-Rodriguez1, F F Casanueva, I Bernabeu.   

Abstract

Certain clinical conditions and markers have recently been demonstrated to modify the natural history of acromegaly in affected patients. Thus, some clinical, histological, radiological and molecular factors are associated with more aggressive pituitary tumors that have higher biochemical activity, higher tumor volumes and decreased tumoral and biochemical responses to current therapies. However, these factors do not seem to have an equal influence on the prognosis of patients with acromegaly. We present a review of the factors that influence the clinical course of patients with acromegaly and propose a risk value for each factor that will allow prognostic scoring for affected patients by considering a combination of these factors.

Entities:  

Mesh:

Year:  2015        PMID: 24858722     DOI: 10.1007/s11102-014-0574-9

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  91 in total

1.  Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.

Authors:  M Filopanti; L Olgiati; G Mantovani; S Corbetta; M Arosio; V Gasco; L De Marinis; C Martini; F Bogazzi; S Cannavò; A Colao; D Ferone; G Arnaldi; F Pigliaru; A Peri; G Angeletti; M L Jaffrain-Rea; A G Lania; A Spada
Journal:  J Clin Endocrinol Metab       Date:  2011-12-07       Impact factor: 5.958

2.  Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission.

Authors:  P De; D A Rees; N Davies; R John; J Neal; R G Mills; J Vafidis; J S Davies; M F Scanlon
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

Review 3.  Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.

Authors:  John S Bevan
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

4.  Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior.

Authors:  K Thapar; K Kovacs; L Stefaneanu; B Scheithauer; D W Killinger; R V Lioyd; H S Smyth; A Barr; M O Thorner; B Gaylinn; E R Laws
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

5.  Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.

Authors:  J Ayuk; R N Clayton; G Holder; M C Sheppard; P M Stewart; A S Bates
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

6.  Gender and age in the biochemical assessment of cure of acromegaly.

Authors:  P U Freda; R E Landman; R E Sundeen; K D Post
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

7.  The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.

Authors:  A J van der Lely; A G Harris; S W Lamberts
Journal:  Clin Endocrinol (Oxf)       Date:  1992-08       Impact factor: 3.478

8.  Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly.

Authors:  Moisés Mercado; Baldomero González; Carolina Sandoval; Yoshua Esquenazi; Fernando Mier; Guadalupe Vargas; Ana Laura Espinosa de los Monteros; Ernesto Sosa
Journal:  J Clin Endocrinol Metab       Date:  2008-07-08       Impact factor: 5.958

Review 9.  Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update.

Authors:  Fateme Salehi; Kalman Kovacs; Bernd W Scheithauer; Ricardo V Lloyd; Michael Cusimano
Journal:  Endocr Relat Cancer       Date:  2008-09       Impact factor: 5.678

10.  Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment.

Authors:  Ana Paula M Casarini; Raquel S Jallad; Emília M Pinto; Iberê C Soares; Suely Nonogaki; Daniel Giannella-Neto; Nina R Musolino; Venâncio A F Alves; Marcello D Bronstein
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

View more
  6 in total

Review 1.  Management of aggressive growth hormone secreting pituitary adenomas.

Authors:  Daniel A Donoho; Namrata Bose; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

2.  Predictors of postoperative biochemical remission in acromegaly.

Authors:  Shun Yao; Wen-Li Chen; Sherwin Tavakol; Farhana Akter; Michael P Catalino; Xiaopeng Guo; Jie Luo; Ai-Liang Zeng; Leo Zekelman; Zhi-Gang Mao; Yong-Hong Zhu; Qing-Zhi Wu; Edward R Laws; Wenya Linda Bi; Hai-Jun Wang
Journal:  J Neurooncol       Date:  2021-01-04       Impact factor: 4.130

3.  Gender differences and temporal trends over two decades in acromegaly: a single center study in 112 patients.

Authors:  Adriana G Ioachimescu; Talin Handa; Neevi Goswami; Adlai L Pappy; Emir Veledar; Nelson M Oyesiku
Journal:  Endocrine       Date:  2019-11-01       Impact factor: 3.633

4.  Potential markers of disease behavior in acromegaly and gigantism.

Authors:  Laura C Hernández-Ramírez
Journal:  Expert Rev Endocrinol Metab       Date:  2020-05-06

5.  Biochemical Control in Acromegaly With Multimodality Therapies: Outcomes From a Pituitary Center and Changes Over Time.

Authors:  Alireza Ghajar; Pamela S Jones; Francisco J Guarda; Alex Faje; Nicholas A Tritos; Karen K Miller; Brooke Swearingen; Lisa B Nachtigall
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

Review 6.  Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?

Authors:  Cheol Ryong Ku; Vladimir Melnikov; Zhaoyun Zhang; Eun Jig Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.